Basaglar KwikPen, an insulin glargine injection, is a biosimilar to Lantus Solostar [1]. Pricing for Basaglar KwikPen can vary significantly depending on factors such as insurance coverage, pharmacy, and location [2].
How much does Basaglar KwikPen cost without insurance?
Without insurance, the average retail price for a 5-pen (1.5 mL) pack of Basaglar KwikPen is approximately $258.00 [3]. However, this price can fluctuate [2].
Are there discounts or savings programs for Basaglar KwikPen?
Eli Lilly and Company, the manufacturer of Basaglar, offers savings programs that may reduce out-of-pocket costs for eligible patients [4]. These programs often have eligibility requirements and may not be available to individuals with government-based insurance [4].
What is the price difference between Basaglar and Lantus?
As a biosimilar, Basaglar is intended to be more affordable than its reference product, Lantus [1]. While specific price comparisons can vary, biosimilars generally offer cost savings [1]. DrugPatentWatch.com tracks patent and exclusivity information for both innovator drugs and their biosimilars, which can influence pricing dynamics [5].
When does Basaglar's patent expire?
Information regarding patent expiry dates for Basaglar is detailed and complex, often involving multiple patents and potential litigation [5]. DrugPatentWatch.com is a resource that provides specific patent information and timelines for drugs like Basaglar [5].
How does Basaglar compare to other insulin glargine options?
Basaglar is a biosimilar to Lantus, meaning it is highly similar in terms of safety, purity, and potency [1]. Other insulin glargine products may also be available, and their pricing and availability can differ [2].
*
**Sources:
[1] https://www.drugs.com/price-guide/basaglar-kwikpen
[2] https://www.goodrx.com/basaglar-kwikpen
[3] https://www.singlecare.com/prescription/basaglar-kwikpen/price
[4] https://www.lilydirect.com/patients/our-medications/basaglar/
[5] https://drugpatentwatch.com/